Under revised terms, AcelRx to acquire Tetraphase for $30.0 million in stock and cash, plus an additional $14.5 million in CVRs Continues to believe Tetraphase acquisition complements AcelRx’s commercial strategy and will deliver long-term shareholder value Co-promotion agreement for XERAVA and DSUVIA proceeding well with teams already integrated
May 27, 2020
· 8 min read